With Novo Nordisk’s Wegovy weight-loss drug in short supply, the company’s owner agreed to buy contract manufacturer Catalent for $16.5 billion, including debt, to boost output.
With Novo Nordisk’s Wegovy weight-loss drug in short supply, the company’s owner agreed to buy contract manufacturer Catalent for $16.5 billion, including debt, to boost output.